As part of the deployment process, the Company will be localizing its Carrier software and documentation to the Russian language, an effort that will enhance RiT's ability to market in the Commonwealth of Independent States (CIS).

Commenting on the news Mr. A. Popov, Technical director of Almatytelecom, the largest branch of JSC Kazakhtelecom, said, "RiT manufactures unique, first class products which will allow us to considerably reduce the quantity of personnel required to carry out our ongoing inventory accounting and management initiatives. The equipment will allow us to automate the preparation and execution of many processes, enabling us to accelerate the completion of our large-scale, national infrastructure and network modernization projects."

The other leading East European telecommunications service provider has been using RiT's PairView Pro systems for the past two years, and is now adding PairView# as part of its strategy for rolling out Next Generation 'Triple Play' services.

Initial deliveries of the equipment were completed during the second quarter, while the majority of the equipment is scheduled to be delivered during the third quarter.

Mr. F. Huber, MD of 3M East AG, commented, "Our cooperation with RiT has enabled us to offer an extremely compelling solution to both Kazakhtelecom and another leading carrier, both of which are leading players in the telecommunications revolution currently underway throughout the CIS. By combining RiT's advanced mapping and monitoring solutions with our product platform, we are able to bring a new level of visibility to the last-mile network, giving operators the tools they need to achieve efficiency in physical plant planning and deployment."

"We are very pleased to report these important sales, both of which demonstrate the success of our sales and support organizations in the CIS and Eastern Europe," added Mr. Avi Kovarsky, RiT's President & CEO. "Our success reflects the strength of our cooperation with 3M, which has enabled us to propose a uniquely comprehensive, field-proven solution. Looking forward, given our expanded regional references and newly localized products, we feel particularly well positioned to continue building our business throughout these dynamic regions."

About RiT Technologies

RiT is a leading provider of physical network infrastructure control and management solutions. Deployed in the networks of many of the world's largest carriers and enterprises, its pioneering, fast-ROI products have proven their ability to simplify service deployment and provisioning, enhance troubleshooting accuracy, reduce infrastructure maintenance costs, enhance physical layer security and enable cost-effective service qualification and verification. For more information, please visit our website:http://www.rittech.com

About 3M Company

A recognized leader in research and development, 3M produces thousands of innovative products for dozens of diverse markets. 3M's core strength is applying its more than 40 distinct technology platforms - often in combination - to a wide array of customer needs. With $24 billion in sales, 3M employs 75,000 people worldwide and has operations in more than 60 countries. For more information, visit http://www.3M.com.

About JSC Kazakhtelecom

JSC Kazakhtelecom is the national telecommunication operator of Kazakhstan and one of the fastest developing telecommunication companies in the Former Soviet Union region. The company currently serves approximately three million subscribers, and is engaged in an extensive project to expand network coverage while modernizing and digitalizing its infrastructure. As a result of its accomplishments, the company was named "Best Telecommunications Company in Central Asia" by Euromoney Magazine in 2006.

In this press release, all statements that are not purely about historical facts, including, but not limited to, those in which we use the words "believe," "anticipate," "expect," "plan," "intend," "estimate", "forecast", "target" and similar expressions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. While these forward-looking statements represent our current judgment of what may happen in the future, actual results may differ materially from the results expressed or implied by these statements due to numerous important factors, including, but not limited to, those described under the heading "Risk Factors" in our most recent Annual Report filed with the Securities and Exchange Commission (SEC) on Form 20-F, which may be revised or supplemented in subsequent reports filed with the SEC. These factors include, but are not limited to, the following: our ability to raise additional financing, if required; the continued development of market trends in directions that benefit our sales; our ability to maintain and grow our revenues; our dependence upon independent distributors, representatives and strategic partners; our ability to develop new products and enhance our existing products; the availability of third-party components used in our products; the economic condition of our customers; the impact of government regulation; and the economic and political situation in Israel. We are under no obligation, and expressly disclaim any obligation, to update the forward-looking statements in this press release, whether as a result of new information, future events or otherwise.

    Company contact:
    Simona Green
    VP Finance
    +972-3-766-4249
    simonag@rit.co.il

SOURCE RiT Technologies Ltd.

"This license agreement will enhance 3M Health Care's rapidly growing advanced wound care business and builds on our reputation as a global leader in the treatment of chronic wounds," said Bill Cruise, Skin and Wound Care Global Business Director, 3M Health Care. "Greystone's innovative PHI technology is proving to be effective in managing hard-to-heal wounds, and combining this technology with our extensive global coverage will benefit patients and clinicians worldwide."

"We have developed an innovative wound care technology that can help patients with chronic and non-responding wounds return to more active and productive lives," said Greg Pilant, Chief Executive Officer, Greystone Pharmaceuticals, Inc. "With 3M Health Care's global presence and deep expertise in advanced wound care, we believe we can bring valuable solutions to patients globally."

About 3M Health Care

3M Health Care, one of 3M's six major business segments, provides world-class innovative products and services to help health care professionals improve the practice, delivery and outcome of patient care in medical, oral care, drug delivery and health information markets.

About Greystone Pharmaceuticals, Inc.

Founded in 1996, and currently headquartered in Fort Myers, Florida, with additional offices in Memphis, Tennessee and Kaatsheuvel, in the Netherlands, Greystone Pharmaceuticals, Inc. is a medical products research and development company that has developed a proprietary, advanced chronic wound care technology for the treatment of non-responsive wounds, particularly in diabetic patients. For more information about Greystone and its products, please visit www.greystonepharmaceuticals.com.

3M and Tegaderm are trademarks of 3M.

PHI is a trademark of Greystone Pharmaceuticals, Inc.

SOURCE: 3M

3M Contact:
3M Public Relations
Glenn Carter, 651-737-0687
gacarter1@mmm.com
or
Greystone Contact:
Mary Liszewski, 239-432-2780
or
239-628-6699
mliszewski@greystonepharmaceuticals.com

Mr. Thulin, a native of Sweden who joined 3M in 1979, succeeds Ronald Baukol, 3M's former executive vice president of international operations and a member of the company's board of directors, who was in turn elected a senior trustee of USCIB.

"I'm delighted to take on the challenge of helping develop USCIB's visibility and effectiveness on the global stage," commented Mr. Thulin. "This is an organization that any company operating in multiple regions of the world ought to participate in. With a unique network, USCIB enables companies to play a direct role in key international organizations that help set the rules of the road for commerce worldwide."

With an MBA degree from Gothenburg University, Sweden, Mr. Thulin has served in diverse marketing, line management and operational capacities in Sweden, Western Europe, Russia, the Asia-Pacific region and at 3M headquarters in Saint Paul, Minn. He was named to his current position with the company in 2003. Mr. Thulin is a director of the board of the Toro Company.

USCIB promotes an open system of global commerce in which business can flourish and contribute to economic growth, human welfare and protection of the environment. Its membership includes more than 300 U.S. companies, professional service firms and associations whose combined annual revenues exceed $3.5 trillion. As American affiliate of the leading international business and employers organizations, USCIB provides business views to policy makers and regulatory authorities worldwide and works to facilitate international trade. More information is available at www.uscib.org.

Contact:
Jonathan Huneke
USCIB
(212) 703-5043
Email Contact

SOURCE: USCIB

http://www2.marketwire.com/mw/emailprcntct?id=67355485EC037380

According to 3M, TLR compounds, also called TLR7 and TLR8 agonists, are small organically synthesized molecules that offer flexibility in formulating and route of delivery, and ease in manufacturing, unlike most other TLR agonists, which are much larger and not as easy to manufacture.

Mark Tomai, head of drug discovery and pre-clinical development at 3M Drug Delivery Systems, said: "IDRI's vaccine platform has the potential to prevent and treat a number of important diseases in the developing world. By providing our vaccine adjuvant compounds to their vaccines, we are providing a cost-effective way for IDRI to conduct vaccine research."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon